Bristol-Myers Squibb Company last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $13.1 billion (+6.9% year over year) and diluted EPS of $1.05. It usually reports 29–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 4, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 5, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
13,069
+6.9%
|
2,162
-1.8%
|
1.05
-2.8%
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
12,973
+5.7%
|
3,317
+153.2%
|
1.62
+153.1%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
11,489
+2.6%
|
2,677
+9.0%
|
1.31
+9.2%
|
|
Feb 5, 2026
36 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
12,502
+1.3%
|
1,087
+1409.7%
|
0.53
+1403.0%
|
|
Oct 30, 2025
30 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
12,222
+2.8%
|
2,201
+81.8%
|
1.08
+80.0%
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
12,269
+0.6%
|
1,310
-22.0%
|
0.64
-22.9%
|
|
Apr 24, 2025
24 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
11,201
-5.6%
|
2,456
+120.6%
|
1.20
+120.4%
|
|
Feb 6, 2025
37 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
12,342
+7.5%
|
72
-95.9%
|
0.04
-95.9%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BMY (NYSE), CELG-RI (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 14272
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.